bioihbjkbjnl/mcl2 huggingface dataset:
Effects of J Stroke Myofascial Release in Patients With Planter Fasciitis
Condition: Plantar Fascitis
MeSH terms: Fasciitis; Fasciitis, Plantar
Study type: Interventional

Summary: 
      The purpose of the study is to compare the effects of j stroke myofascial release on planter
      fascia versus ischemic release on gastrocnemius in patients with planter fasciitis.
    

Detailed description: 
      Planter fasciitis is commonly occur in athletes and females who wear flat shoes. It is caused
      by the loss of planter fascia flexibility that leads to mechanical overloading of fascial
      structures. There are some risk factors that are important to consider include age, leg
      length difference, inadequate footwear, inappropriate walking and running patterns and
      increased planter fascia thickness. Planter fascia thickness more than 4mm can be considered
      as an indicative of planter fasciitis.

      Myofascial soft tissue mobilization is a low load, long duration stretch to the myofascial
      complex technique that is given in both acute and chronic conditions which in caused by
      tightness and soft tissue restriction in the patients with planter fasciitis to restore
      length, decrease pain and to improve function.

      Cupping therapy on gastrocnemius is a medical technique that applies negative pressure over
      pain areas and pressure points that alleviates pain and improve blood circulation. it could
      be low-cost and convenient alternative technique to treat planter fasciitis.
    

Intervention name(s): J Stroke Myofascial Release; Ischemic Release on Gastrocnemius through Dry Cupping
Intervention type(s): Other; Other
Intervention description(s): Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.; Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: planter fascitis; J stroke myofascial release; Ischemic release on gastrocnemius
Insufflation in Children Undergoing Colonoscopy
Condition: Colonoscopy; Children
Study type: Interventional
Phase: Phase 4

Summary: 
      Studies in adults have shown that post-procedural abdominal pain is reduced with the use of
      CO2 instead of air for insufflation during colonoscopy. The aim of our study is to compare
      post-procedural abdominal pain and girth in children undergoing colonoscopy using CO2 or air
      for insufflation.
    

Detailed description: 
      Several prospective studies in adults have confirmed the efficacy and safety of CO2
      insufflation in comparison with atmospheric air insufflation during colonoscopy. CO2
      insufflation was associated with decreased post-procedural abdominal pain, which likely stems
      from the fact that, in comparison to air, absorption of CO2 from the colon is much faster due
      to a much greater water solubility. Animal studies have also shown that CO2 insufflation
      results in less disturbance of parietal blood flow due to its potential vasodilating effect.
      Insufflation of colon with CO2 did not prolong the procedure or lengthen the time to reach
      the terminal ileum and was proven to be safe in both sedated and non-sedated patients . The
      use of CO2 for colon insufflation could possibly lead to CO2 retention and increased levels
      in the blood thus interfering with acid-base balance . However, previous studies reported
      that carbon dioxide insufflation did not cause increased CO2 levels in the blood or end-tidal
      CO2 (ETCO2) and complication rates were not increased when using CO2. Because of its
      advantages CO2 insufflation has become a standard of care in adult colonoscopy.

      To the best of our knowledge there are so far no published reports comparing CO2 and air
      insufflation during colonoscopy in children.
    

Intervention name(s): CO2; air
Intervention type(s): Other; Other
Intervention description(s): gas; air
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Prevention
Keywords: insufflation; abdominal pain
Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models
Condition: Urea Cycle Disorders, Inborn; Other Metabolic Diseases
MeSH terms: Urea Cycle Disorders, Inborn; Metabolic Diseases
Study type: Interventional

Summary: 
      Montmorillonite (MONT) is a phyllosilicate layered mineral with unique physicochemical
      properties, such as swelling and cation exchange capability.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake. Furthermore, the study analyzed in vitro the MONT ability
      of immobilizing proteins.
    

Detailed description: 
      Montmorillonite (MONT) is a phyllosilicate layered mineral; chemically it is hydrated sodium
      calcium aluminium magnesium silicate hydroxide. Potassium, iron, and other cations are common
      substitutes and the exact ratio of cations varies with source.

      Due to its unique physicochemical properties, such as swelling and cation exchange
      capability, as well its mechanical and thermal stability, MONT can be efficiently used as
      matrix for immobilization of proteins with high molecular weight (e.g. Albumin) and proteins
      with low molecular weight (e.g.Aflatoxines). Therefore, MONT is used for therapeutic
      purposes, in pharmaceutical formulations and in food preparations. In vitro assays made in
      our laboratory, showed that MONT absorbs, in stable manner, alimentary proteins:
      beta-lactoglobulins, alfa lactoalbumines and the ratio MONT-protein (w/w) 1:3, 1:5, 1:15,
      results in the protein capture of 50, 27, 0 % of proteins respectively.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake evaluated with the blood MONT- protein ratio. Furthermore,
      the study analyzed in vitro the MONT ability of immobilizing proteins at different ratio
      (w/w) 1:3, 1:5, 1:15.
    

Intervention name(s): montmorillonite 5 g; montmorillonite 3 g; Montmorillonite 1 g
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): 5g montmorillonite + 15 g protein (ratio 1:3); 3g MONT+ 15 g protein (ratio 1:5); 1g MONT+ 15 g protein (ratio 1:15)
Intervention MeSH terms: Bentonite
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: Montmorillonite, proteic diet, in vitro and in vivo models
Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting
Condition: Type 1 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 1
Study type: Interventional

Summary: 
      This study is a randomized controlled trial assessing diabetes knowledge (using a Mercy-What
      I Know About Diabetes Test (MWIKAD) validated survey) and self-care practices (using a
      validated Self-management of Type 1 Diabetes-Adolescence (SMOD-A) survey) at baseline, 3
      months and 6 months. The intervention group will receive a minimum of 78 text messages
      related to diabetes over the course of 26 weeks from study enrollment. Subjects are invited
      to respond to some text messages which will be in the form of a multiple-choice question and
      if they do, they will receive an additional text message in response to their answer.
    


Intervention name(s): Texting
Intervention type(s): Behavioral
Intervention description(s): From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: adolescent; young adult; knowledge; self-care
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
Condition: Renal Insufficiency
MeSH terms: Renal Insufficiency
Study type: Interventional
Phase: Phase 2

Summary: 
      This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in
      subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction,
      or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In
      addition, this study compared the behavior of a single dose of Met DR with that of
      extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney
      function described above.
    


Intervention name(s): Met DR; Met XR; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): metformin delayed-release tablets; metformin extended-release tablets
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
Condition: Embolic Stroke
MeSH terms: Embolic Stroke; Embolism; Recurrence
Study type: Interventional
Phase: Phase 4

Summary: 
      This is a randomized, double blind, placebo-controlled, parallel, multicenter research in
      order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or
      asymptomatic new cerebral infarction within 10 days.

      Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential
      causes of Embolic Stroke of Undetermined Source (ESUS).
    

Detailed description: 
      Shuxuetong injection or Placebo injection for 10days. About 2416 patients randomized at 80
      centers all over China with 20 subgroup study centers.

      Face to face interview at baseline, 10 days, and 90 days.
    

Intervention name(s): Shuxuetong Injection; Placebo Injection
Intervention type(s): Drug; Drug
Intervention description(s): intravenous drip; intravenous drip
Other intervention name(s): Shuxuetong; Placebo
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: Stroke; Embolic Stroke; Shuxuetong; Recurrence; Symptomatic New Cerebral Infarction; Asymptomatic New Cerebral Infarction
Influence of Virtual Reality Games on Knee Proprioception After Anterior Cruciate Ligament Reconstruction (ACLR)
Condition: Motor Activity; Proprioceptive Disorders; Balance; Distorted
MeSH terms: Somatosensory Disorders
Study type: Interventional

Summary: 
      Influence of virtual reality games(Wii Fit) on knee proprioception after anterior cruciate
      ligament reconstruction (ACLR) will be measured in 30 postoperative patients. The age of
      participants will be ranged from 20 to 30 years old. Subjects will be randomly assigned to
      Group A is the study group and Group B is the control group.
    

Detailed description: 
      Group A will receive the Wii fit protocol of virtual reality games, in addition to the
      regular exercise rehabilitation protocol, for 3 non-consecutive days per week, for 8 weeks ,
      40 minutes for each session. Group B will receive the regular exercise rehabilitation
      protocol only for 3 non-consecutive days per week for 8 weeks, 40 minutes for each session.

      A Universal Weight and Height Scale: will be used to measure the patient's BMI.

      Biodex Isokinetic Dynamometer: will be used to assess the knee proprioception of the affected
      operated leg at three target angles (30,45,and 60 degrees).
    

Intervention name(s): Wii fit protocol of virtual reality games; Regular exercise rehabilitation protocol
Intervention type(s): Procedure; Procedure
Intervention description(s): the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .; It will be according to the criterion of Adams et al. (2012).
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: There are two group of subjects:
Group A (study group).
Group B:(Control group).
Masking: None (Open Label)
Primary purpose: Treatment
Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects
Condition: HIV Infections
MeSH terms: HIV Infections
Study type: Interventional
Phase: Phase 1

Summary: 
      The objective was to establish the pharmacokinetic (PK) profile at steady state of two
      different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD)
      under fasted and fed conditions in comparison with the commercially available NVP immediate
      release (IR) tablet at 200 mg BID (400 mg/day).
    


Intervention name(s): NVP XR 400 mg (KCR 25%); NVP XR 400 mg (KCR 20%); NVP XR 300 mg (KCR 25%); NVP XR 300 mg (KCR 20%); high-fat breakfast; NVP IR 200 mg (Viramune®)
Intervention type(s): Drug; Drug; Drug; Drug; Other; Drug
Intervention MeSH terms: Nevirapine
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With Chronic Fatigue Syndrome
Condition: Chronic Fatigue Syndrome
MeSH terms: Fatigue Syndrome, Chronic; Syndrome; Fatigue
Study type: Interventional

Summary: 
      The aim of this study is to determine the efficacy of FITNET (web-based cognitive behavioural
      treatment) for adolescents with Chronic Fatigue Syndrome (CFS) in The Netherlands. The second
      goal of the study is to establish predictors of outcome. It is very important to know the
      characteristics of patients who will benefit from Cognitive Behavioural Treatment (CBT) and
      who will not. Possible predictors of outcome are: age, depression, anxiety, fatigue of the
      mother, parental bonding, self-efficacy, body consciousness of child and mother, physical
      activity (Actometer).
    

Detailed description: 
      All participants will be randomized to one of the two treatment arms:

        1. Intervention with web-based cognitive behavioral treatment

        2. Usual care

      The duration of the cognitive behavioural program is limited to 6 months. The adolescents who
      have been assigned to the usual care will get the opportunity to attend the program after
      these 6 months. The total follow-up time is 12 months after the start of the web-based
      program.

      The web-based program is developed for both the adolescents and the parents. The program
      consists of two parts, a psycho-educational part and a cognitive behavioural part consisting
      of 21 treatment modules. The therapist activates one or more treatment modules per week,
      dependent on the progress of the participant. Within a treatment module the participant will
      keep several journals, answer questions and do several assignments. All answers are sent to
      the therapist, with whom a weekly email contact will be realized.

      Efficacy of the web-based program will be determined after 6 months. There will be a
      follow-up measurement at 12 months.
    

Intervention name(s): FitNet treatment; Usual care
Intervention type(s): Behavioral; Other
Intervention description(s): web-based cognitive behavioural treatment for adolescents with CFS; Usual care treatment for adolescents with CFS
Other intervention name(s): CBT; Internet treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Chronic Fatigue Syndrome (CFS); Adolescence; Cognitive behaviour therapy (CBT); Web-based; Internet; Efficacy
XC8 in the Treatment of Patients With Acute Respiratory Viral Infection
Condition: Influenza; Acute Respiratory Infection
MeSH terms: Infections; Communicable Diseases; Influenza, Human; Respiratory Tract Infections; Virus Diseases
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      A multicenter double-blind, randomized, placebo-controlled, parallel-group comparative Phase
      II / III clinical study to assess safety, tolerability, efficacy and optimal dose ranging of
      XC8 vs. placebo in patients with uncomplicated influenza or other ARVI during a 5-day
      treatment.

      The primary objective of the study was to demonstrate the difference in time before the onset
      of a sustained improvement in clinical symptoms according to the Severity Rating Scale for
      ARVI, and to determine the optimal dose of XC8 in the treatment of influenza and other ARVI.
    

Detailed description: 
      Twenty-three Russian centers were approved for participation in this study. Twenty centers
      were initiated. Patients were enrolled in 18 centers. The study consisted of two parts: phase
      II and phase III. Each of the parts included 3 periods: screening, treatment, follow-up.

      In the first part of the study (Phase II), all eligible patients were randomized into 4
      groups (groups A, B, C, and D) in a 1:1:1:1 ratio:

      Group A - XC8 20 mg daily (40 patients); Group B - XC8 100 mg daily (40 patients); Group C -
      XC8 200 mg daily (40 patients); Group D - placebo (40 patients).

      Interim analysis was planned after the end of the first part of the study (Phase II). Based
      on the results of the interim analysis, the most promising XC8 dose group was selected and
      the necessary set was calculated to compare this group with the placebo group by the primary
      endpoint in a pooled set using an adaptive design with type I error control.

      In the second part of the study (Phase III), all eligible patients were randomized into 2
      groups (groups C and D) in a 1:1 ratio:

      Group C - XC8 200 mg daily (80 patients); Group D - placebo (80 Patients).

      During the treatment period (5 days), patients received XC8 / placebo daily on a background
      of standard symptomatic therapy. The follow-up period lasted for 9 days.
    

Intervention name(s): XC8 20 mg; XC8 100 mg; XC8 200 mg; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): once daily during 5 days.; once daily during 5 days.; once daily during 5 days.; once daily during 5 days.
Other intervention name(s): Нistamine glutarimide; Нistamine glutarimide; Нistamine glutarimide
Intervention MeSH terms: Histamine; Histamine phosphate; Glutarimide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Ibuprofen Versus Ketorolac for Perioperative Pain Control After Open Hysterectomy
Condition: Postoperative Pain; Hysterectomy
MeSH terms: Pain, Postoperative
Study type: Interventional

Summary: 
      The aim of this study is to compare the analgesic effect of intravenous ibuprofen to
      ketorolac for pain control after open hysterectomy
    

Detailed description: 
      Thirty minutes before the surgery, all patients will receive 1 gm paracetamol intravenously
      then every 6 hours postoperatively.

      A research assistant is responsible for opening the envelopes, group assignment and drug
      preparation (the three doses will be prepared and marked with the patient's name as well as
      the time of administration) without any further involvement in the study. The patient,
      attending anesthetist, nurse and data collector will be blinded to the administered drug.

      Upon arrival to the operating room, routine monitors (electrocardiogram, pulse oximetry, and
      non-invasive blood pressure monitor) will be applied; intravenous line will be secured, and
      prophylactic antiemetic will be provided in the form of slow intravenous injection of 8 mg
      dexamethasone drugs.

      Anesthesia Anesthesia will be induced with 2 mg/kg propofol, 1 mcg/kg fentanyl, and tracheal
      intubation will be facilitated by 0.5 mg/kg atracurium after loss of consciousness.
      Anesthesia will be maintained with isoflurane 1-1.2% in oxygen and 0.1 mg/kg atracurium every
      20 minutes. Intraoperative analgesia will be in the form of 1 mcg/kg fentanyl boluses as
      needed.

      Postoperatively, pain assessments using the visual analogue scale (VAS) will be performed at
      rest and during movement (knee flexion) at 0.5, 2, 4, 6, 10, 18, and 24 h after leaving the
      operating room. If the VAS score is > 3 intravenous titration of 2 mg morphine given slowly
      to be repeated after 30 minutes if pain persisted.

      Intravenous ondansetron 4 mg will be given to treat postoperative nausea or vomiting
    

Intervention name(s): Ketorolac Injectable Solution; Ibuprofen 800 mg
Intervention type(s): Drug; Drug
Intervention description(s): ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively; ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
Intervention MeSH terms: Ibuprofen; Ketorolac
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection
Condition: Aortic Diseases
MeSH terms: Aortic Diseases
Study type: Interventional

Summary: 
      The purpose of this study is to compare endoluminal stent grafting with the GORE TAG device
      and Best Medical Therapy (BMT) to BMT alone in the treatment of acute uncomplicated type B
      aortic dissections.
    

Detailed description: 
      Dissection of the aorta is a medical emergency requiring immediate surgery. Type B
      dissections are typically treated with surgery or endoluminal therapy when complications such
      as uncontrollable pain, organ ischemia, or aortic rupture are present. However, the treatment
      of patients with uncomplicated, acute type B dissections is controversial. Best medical
      therapy (BMT) is the standard of care in these cases since surgical repair offers no
      additional survival advantage. However, Endoluminal stent graft therapy with the GORE TAG
      Thoracic Endoprosthesis (GORE TAG device) may offer distinct advantages as an adjunct to
      medical therapy for uncomplicated acute type B dissection. The goal of endoluminal stent
      grafting is to cover the primary entry tear of the dissection to isolate the false lumen from
      blood flow and induce aortic remodeling.
    

Intervention name(s): Gore TAG Endoprosthesis; Best Medical Therapy
Intervention type(s): Device; Other
Intervention description(s): Implant Gore TAG device with Best Medical therapy per physician discretion; Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment